Background. Although isolated abnormalities of plasminogen activation and inhibition have been reported among selected patients with venous thrombosis, it is unclear whether these deficiencies of fibrinolysis are important risk factors for thromboembolic disease.
although the positive predictive value of an isolated protein deficiency in unselected patient populations is low. 3 Recently, a fast-acting plasminogen activator inhibitor (PAI-1) has been described that, by binding to circulating tissue-type plasminogen activator (t-PA), plays a major role in determining fibrinolytic state. [4] [5] [6] In selected patients with deep venous thrombosis and pulmonary embolism, elevated levels of PAI-1 have been reported, often in conjunction with low levels of endogenous t-PA activity.7-15 In one report, the prevalence of diminished plasminogen activation and/or elevated plasminogen inhibition among individuals with venous thrombosis was between 15% and 30%.12 These data, however, have generally been derived from small and uncontrolled case series or from retrospective studies with inherent methodological limitations. Furthermore, evidence has accumulated that PAI-1 is part of the acute phase reaction,'6'7 suggesting that studies of patients with recent thrombotic events may be misleading, especially if alterations in fibrinolytic state are a consequence rather than a cause of vascular thrombosis. Thus, a prospective study of PAI-1 and endogenous t-PA activity among healthy individuals that includes information on other cardiovascular risk factors is nec-essary to determine whether baseline alterations of these fibrinolytic parameters are associated with increased risks of future venous thrombosis.
The Physicians' Health Study (PHS),18 a large-scale randomized trial, afforded the opportunity to assess in prospective data whether baseline PAI-1 and t-PA antigen levels in apparently healthy individuals are predictive of future venous thrombosis. In this article, we report the results of a nested case-control study using the PHS cohort in which baseline PAI-1 and t-PA levels among 55 individuals who subsequently developed deep venous thrombosis or pulmonary embolism were compared with 55 control subjects matched for age, sex, and smoking habit who remained free of vascular events during a mean follow-up period of 60.2 months.
Methods

Study Population and Blood Collection
Detailed descriptions of the PHS, a randomized double-blind, placebo-controlled trial of aspirin in the prevention of cardiovascular disease and fl-carotene in the prevention of cancer, have been given elsewhere. 18 In brief, 22,071 US male physicians aged 40-84 years in 1982 and free of previous myocardial infarction, stroke, transient ischemic attack, and cancer were randomly assigned to one of four treatment groups: 325 mg of active aspirin and 50 mg of active fl-carotene, active aspirin and placebo fl-carotene, placebo aspirin and active fl-carotene, or placebo aspirin and placebo fl-carotene. Six months after randomization and annually thereafter, questionnaires assessing various health outcomes and risk factors have been mailed and returned by these physicians, with 100% mortality follow-up and 99.7% morbidity follow-up. The aspirin component of the trial was terminated early on January 25, 1988, after a mean of 60.2 months of treatment and follow-up, primarily because of a statistically extreme 44% reduction in the occurrence of a first myocardial infarction in the aspirin group. The randomized, double-blind, placebo-controlled fl-carotene component of the PHS is ongoing.
Before randomization, between 1982 and 1984, all physicians being evaluated to participate in the PHS were assigned to a regimen of active aspirin and placebo fl-carotene in an 18-week run-in to obtain a group of high compliers for long-term follow-up. During the run-in, all participants were asked to provide baseline blood plasma samples. Kits including EDTA vacutainer tubes and plastic NUNC vials were sent to each physician along with instructions for blood drawing. Participants were asked to have their blood drawn into the EDTA tubes, centrifuge the tubes, and return the plasma, accompanied by a cold pack, by overnight courier. The time of day phlebotomy occurred was also recorded. Upon arrival in the laboratory, specimens were aliquoted and stored at -80°C. Approximately 68% of the randomized physicians returned a baseline blood sample specimen (14,916 subjects).
Ascertainment of Venous Thrombosis
Hospital records and/or death certificates were requested for all reported cardiovascular disease end points (including deep venous thrombosis and pulmo-nary embolism). These medical records, death certificates, and autopsy reports were then reviewed by an end-points committee of physicians using standardized criteria to confirm or refute each reported diagnosis.
The diagnosis of deep venous thrombosis was confirmed by documentation of a positive venography study or a positive ultrasound study. Reported deep venous thromboses documented only by impedance plethysmography or Doppler examination without ultrasound were not confirmed.
The diagnosis of pulmonary embolism was confirmed by a positive angiogram or a completed ventilation-perfusion scan that demonstrated at least two separate segmental perfusion defects with normal ventilation.19 Reported pulmonary emboli documented by perfusion scans alone or by subsegmental defects were not confirmed.
Selection of Case Patients and Control Subjects
We used a prospective nested case-control design within the PHS. Each physician with a confirmed deep venous thrombosis and/or pulmonary embolism occurring after the date of randomization who provided an adequate baseline plasma sample was matched to one control subject. Control subjects were randomized physicians who provided a baseline plasma sample and who remained free of any vascular disease at the time of matching. Control subjects were selected at random from participants who met the matching criteria of age (+ 1 year), smoking habit (current, past, or never smoker), and time since randomization by 6-month intervals. Between initial randomization in 1982 and the termination of the aspirin component of the PHS in 1988, 55 cases of deep venous thrombosis or pulmonary embolism were reported, confirmed, and assigned a control subject matched according to the above criteria. These 55 case-control pairs form the basis for these analyses.
Ascertainment of Baseline PAI-1 and t-PA Levels
For each case patient and each control subject, stored plasma was thawed and assayed for PAI-1 and t-PA antigen levels by a two-site ELISA using kits purchased from Biopool AB, Umea, Sweden. Assays were performed in accordance with the manufacturer's instructions according to a procedure described by Ranby et al. 20 Briefly, plasma samples were incubated in microtiter plates coated with monoclonal antibodies against the desired antigen, unbound antigens were washed off, and bound antigen was detected by addition of a second specific antibody conjugated to horseradish peroxidase. Standard curves are constructed using dilutions of purified antigen in plasma. The amount of PAI-1 or t-PA in samples is deduced by comparing the sample absorbance with the calibration curve. Previous studies have shown the intra-assay coefficients of variance to be 5.1% for PAI-1 and 6.0% for t-PA20; in our laboratory, with frozen stored samples from our study, these values are 8.7% and 6.1%, respectively.
Case and control blood specimens were analyzed in pairs, with the position of the case specimens varied at random within pairs, to avoid systematic bias and interassay variability. All laboratory personnel were blinded to case or control status. Every fifth assay was performed twice to ensure consistency between assay measurements. Eight blinded samples of standard 
Determination of Baseline Cardiovascular Risk Factors
In addition to providing blood samples before randomization, participating physicians also reported risk factors that included age and smoking status (the matching variables) as well as height, weight, systolic and diastolic blood pressures (mm Hg), history of elevated cholesterol, parental history of myocardial infarction before age 60 years (yes/no), alcohol consumption (drinks per day), and vigorous exercise (times per week).
Statistical Analysis
Means or proportions for baseline cardiovascular risk factors were calculated for case patients and control subjects. The significance of any differences in means between the case and control groups was tested by Student's t test. The significance of any differences in proportions was tested by the x2 statistic.
To assess the significance of any differences in mean baseline PAI-1 and t-PA antigen levels among case patients and control subjects, a matched-pair analysis was performed using a paired t test statistic. A x2 test for trend was used to assess for any relation between increasing levels of PAI-1 or decreasing levels of t-PA (as defined by quartiles in the control group) and the risk of future deep venous thrombosis and pulmonary embolism. Similar analyses were performed for the baseline PA-li:t-PA ratio after each antigen measure was converted to a molar quantity (PA-i: t-PA). To assess whether baseline cardiovascular risk factors other than the matching criteria of age, sex, and smoking habit affected these relations, adjusted estimates of risk were also obtained from a conditional logistic regression model that controlled simultaneously for systolic and diastolic blood pressures, body mass index, history of angina, history of elevated blood cholesterol, history of diabetes mellitus, pattern of alcohol consumption, and randomized treatment assignment.
Results
Baseline characteristics of the 55 case-control pairs are shown in Table 1 . Because case patients and control subjects were matched for age, sex, and smoking habit, the distribution of these variables was identical. Frequent alcohol use was less common in case patients than in control subjects (p=0.03). No statistically significant differences were found between case patients and control subjects for other baseline characteristics, including systolic and diastolic blood pressures, body mass index, and exercise frequency. Similarly, no statistically significant differences were found between case patients and control subjects in terms of randomized assignment to aspirin and/or ,8-carotene.
Overall, mean baseline levels of PAI-1, t-PA, and PAI-: t-PA ratio were not statistically different between the case and control groups, as shown in Table 2 . Specifically, the mean baseline PAI-1 antigen level for the 55 cases of deep venous thrombosis or pulmonary embolism was 50.5 ng/ml compared with 59.5 ng/ml for control subjects (95% confidence interval for the -9.0-ng/ml difference between case patients and control subjects: -24.7 ng/ml, +6.6 ng/ml; p=0.26). For t-PA, the mean baseline antigen level was 13.4 ng/ml for case patients and 13.3 ng/ml for control subjects (95% confidence interval for the +0.i-ng/ml difference between case patients and control subjects: -1.5 ng/ml, + 1.6 ng/ml;p=0.94). Finally, the mean baseline PA-l: t-PA ratio was 6.8 for case patients compared with 6.6 for control subjects (95% confidence interval for the +0.2 difference between case and control: -1.9, +2.4; p =0.82).
The distributions of the case patients and control subjects are presented graphically in Figures 1-3 for baseline PAI-1, t-PA, and the PA-1: t-PA ratio, respectively. The distributions appear to be virtually identical. Specifically, there is no suggestion that elevated PAI-1 levels or decreased t-PA levels are preferentially associated with case patients rather than control subjects.
To assess further whether an increased risk of future deep venous thrombosis or pulmonary embolism is associated with increasing levels of PAI-1, decreasing levels of t-PA, or increasing levels of the PA-i: t-PA ratio, a test for trend across sequential quartiles for each of these variables was performed, with quartiles defined by the control population. No To address the possibility that chronic low-dose aspirin use may have inhibited thrombosis in our population to a degree sufficient to reduce a true association between PAI-1 or t-PA and subsequent venous thrombosis, an additional analysis was performed for those individuals who were not assigned to active aspirin therapy. In this subgroup, no apparent trend toward increasing risk of venous thrombosis was found for quartiles of PAI-1 (p=0.86), t-PA (p=0.96), or PAIi :t-PA ratio (p=0.44) after control for ,-carotene assignment.
Finally, because fibrinolytic parameters may vary depending on the time of day that blood sampling occurs, we repeated these analyses for a subgroup of 33 case-control pairs for whom the time of day of blood drawing differed by <3 hours. No statistically significant differences in baseline levels of PAI-1, t-PA, or the PA-1: t-PA ratio were observed in this subgroup analysis (Table 3 ).
Discussion
The current data indicate that baseline levels of PAI-1 and t-PA antigen do not predict the future occurrence of deep venous thrombosis or pulmonary embolism among apparently healthy individuals. Specifically, among 55 randomized participants in the PHS who developed deep venous thrombosis or pulmonary embolism during 60.2 months of follow-up, mean baseline levels of PAI-1 and t-PA were not different from those measured among a group of 55 age-, sex-, and smoking-matched controls who remained free of cardiovascular disease. Overall, the distributions of these antigens at baseline were virtually identical between the case patients and control subjects. At no quartile of antigen as defined by the control subjects was the proportion of case patients significantly different from that which would be expected by chance alone, nor was any evidence of a trend between increasing PAI-1 levels or decreasing t-PA levels and the future occurrence of venous thrombosis observed. These relations were not altered after control for a variety of other vascular risk factors or in the subgroup for which there was no difference between case patients and control subjects with respect to the time of day of blood sampling.
Previous studies have suggested that elevations of PAI-1 and deficiencies of endogenous t-PA are often associated with venous occlusion.7 However, these findings were generally derived from uncontrolled case series or small retrospective studies, often analyzing highly selected patients specifically referred for the evaluation of recurrent thrombosis or familial thrombophilia.
In contrast, our data, collected prospectively in a controlled clinical trial, do not support the hypothesis that baseline levels of PAI-1 and t-PA predict the occurrence of vascular occlusion among previously healthy men. We therefore believe it is unlikely that screening tests for baseline fibrinolytic capacity, as measured by PAI-1 and endogenous t-PA, will be of major clinical use in the identification of patients at high risk for deep venous thrombosis and pulmonary embolism. This finding is consistent with the recent report that screening is also of limited benefit for other abnormalities of coagulation and fibrinolysis such as protein C, protein S, and anti-thrombin III.3
The current data do not imply that no relation exists between markers of fibrinolytic state and the occurrence of venous thromboembolism. Patients with familial recurrent thromboses probably represent an unusual group of patients at particularly high risk because of genetic alterations in PAI-1 and t-PA.13-'5 Furthermore, preoperative values of PAI-1 appear to be predictive of postoperative venous occlusion,9 and in mice transgenic for the PAI-1 gene, elevated levels of this protein contribute to the development of venous thrombosis.21 Our data do suggest, however, that random baseline sampling of t-PA and PAI-1 antigen will not effectively categorize fibrinolytic state for the purposes of clinical screening in the general population, where the overwhelming majority of deep venous thrombosis and pulmonary embolism occurs. This finding is consistent with the hypothesis that the process of local venous thrombosis represents a dynamic relation between promotors and inhibitors of coagulation, the levels of which may fluctuate over time or in response to specific stimuli. This hypothesis is supported by the fact that t-PA and PAI-1 appear to be part of the acute-phase response16'7 and may display circadian variations in activity. 22.23 The potential limitations of this study must be considered. First, baseline blood samples were frozen at -80°F for as long as 6 years before undergoing assay for t-PA and PAI-1, raising the possibility that these proteins may have degraded over time, resulting in an underestimation of true baseline antigen level. Such random misclassification, if present, could in theory account for a finding of no association. However, al- though no direct confirmation of measures of PAI-1 and t-PA antigen levels after a prolonged period of freezing are available, previous work has demonstrated that most proteins and antibodies remain stable in such conditions.2425 In addition, the fact that very few subnormal levels of PAI-1 or t-PA were found in this study provides indirect but reassuring evidence against any systematic protein degradation in these samples. It should also be noted that both the case and control groups included several participants whose measures of PAI-1 antigen were unusually high (>100 ng/ml), possibly indicating the presence of secreted PAI-1 from platelets. As the participants in our study were all taking active aspirin at the time of blood collection, one might speculate that some association exists between this antiplatelet agent and the occasional high levels of PAI-1 observed. However, several authors have previously demonstrated that aspirin therapy causes no change in resting levels of t-PA antigen or PAI-1.26-29 This finding is extended by our data, as the relations between baseline fibrinolytic state and future risks of venous thrombosis appear to be independent of aspirin randomization. In addition to random misclassification explaining a null result, the possibility exists that our sample size was not adequate to detect a significant difference between case patients and control subjects. In this regard, the 95% confidence intervals in our data indicate that it is highly unlikely that any true difference between case patients and control subjects exists that would be greater than +6.6 ng/ml for PAI-1 or -1.5 ng/ml for t-PA, levels far smaller than those postulated to be of biological importance. Furthermore, it is interesting to note that case patients in this sample actually had, on average, lower levels of PAI-1 and higher levels of t-PA than did control subjects, a finding in opposition to the a priori hypothesis.
In sum, these prospective data from a cohort of middle-aged men indicate that baseline fibrinolytic state as measured by PAI-1 and t-PA does not predict the occurrence of future venous thrombosis. Although further prospective studies of hemostatic risk factors to either confirm or refute these findings are necessary, at present these data provide evidence against routine screening for baseline fibrinolytic capacity to predict future venous thrombosis.
